96 related articles for article (PubMed ID: 19924781)
1. Large intragenic deletions of the NF2 gene: breakpoints and associated phenotypes.
Abo-Dalo B; Kutsche K; Mautner V; Kluwe L
Genes Chromosomes Cancer; 2010 Feb; 49(2):171-5. PubMed ID: 19924781
[TBL] [Abstract][Full Text] [Related]
2. Screening for large mutations of the NF2 gene.
Kluwe L; Nygren AO; Errami A; Heinrich B; Matthies C; Tatagiba M; Mautner V
Genes Chromosomes Cancer; 2005 Apr; 42(4):384-91. PubMed ID: 15645494
[TBL] [Abstract][Full Text] [Related]
3. Molecular characterization of germline NF2 gene rearrangements.
Legoix P; Sarkissian HD; Cazes L; Giraud S; Sor F; Rouleau GA; Lenoir G; Thomas G; Zucman-Rossi J
Genomics; 2000 Apr; 65(1):62-6. PubMed ID: 10777666
[TBL] [Abstract][Full Text] [Related]
4. Severe phenotype of neurofibromatosis type 2 in a patient with a 7.4-MB constitutional deletion on chromosome 22: possible localization of a neurofibromatosis type 2 modifier gene?
Bruder CE; Ichimura K; Blennow E; Ikeuchi T; Yamaguchi T; Yuasa Y; Collins VP; Dumanski JP
Genes Chromosomes Cancer; 1999 Jun; 25(2):184-90. PubMed ID: 10338003
[TBL] [Abstract][Full Text] [Related]
5. Sensitive detection of deletions of one or more exons in the neurofibromatosis type 2 (NF2) gene by multiplexed gene dosage polymerase chain reaction.
Diebold R; Bartelt-Kirbach B; Evans DG; Kaufmann D; Hanemann CO
J Mol Diagn; 2005 Feb; 7(1):97-104. PubMed ID: 15681480
[TBL] [Abstract][Full Text] [Related]
6. The location of constitutional neurofibromatosis 2 (NF2) splice site mutations is associated with the severity of NF2.
Baser ME; Kuramoto L; Woods R; Joe H; Friedman JM; Wallace AJ; Ramsden RT; Olschwang S; Bijlsma E; Kalamarides M; Papi L; Kato R; Carroll J; Lázaro C; Joncourt F; Parry DM; Rouleau GA; Evans DG
J Med Genet; 2005 Jul; 42(7):540-6. PubMed ID: 15994874
[TBL] [Abstract][Full Text] [Related]
7. Impairment of cell adhesion by expression of the mutant neurofibromatosis type 2 (NF2) genes which lack exons in the ERM-homology domain.
Koga H; Araki N; Takeshima H; Nishi T; Hirota T; Kimura Y; Nakao M; Saya H
Oncogene; 1998 Aug; 17(7):801-10. PubMed ID: 9779996
[TBL] [Abstract][Full Text] [Related]
8. Identification and characterization of large deletions in the phenylalanine hydroxylase (PAH) gene by MLPA: evidence for both homologous and non-homologous mechanisms of rearrangement.
Kozak L; Hrabincova E; Kintr J; Horky O; Zapletalova P; Blahakova I; Mejstrik P; Prochazkova D
Mol Genet Metab; 2006 Dec; 89(4):300-9. PubMed ID: 16931086
[TBL] [Abstract][Full Text] [Related]
9. Phenotypic variability associated with 14 splice-site mutations in the NF2 gene.
Kluwe L; MacCollin M; Tatagiba M; Thomas S; Hazim W; Haase W; Mautner VF
Am J Med Genet; 1998 May; 77(3):228-33. PubMed ID: 9605590
[TBL] [Abstract][Full Text] [Related]
10. A point mutation associated with a severe phenotype of neurofibromatosis 2.
MacCollin M; Braverman N; Viskochil D; Ruttledge M; Davis K; Ojemann R; Gusella J; Parry DM
Ann Neurol; 1996 Sep; 40(3):440-5. PubMed ID: 8797533
[TBL] [Abstract][Full Text] [Related]
11. Alport syndrome. Molecular genetic aspects.
Hertz JM
Dan Med Bull; 2009 Aug; 56(3):105-52. PubMed ID: 19728970
[TBL] [Abstract][Full Text] [Related]
12. Characterisation of 16 polymorphic markers in the NF2 gene: application to hemizygosity detection.
Legoix P; Legrand MF; Ollagnon E; Lenoir G; Thomas G; Zucman-Rossi J
Hum Mutat; 1999; 13(4):290-3. PubMed ID: 10220142
[TBL] [Abstract][Full Text] [Related]
13. Further genotype--phenotype correlations in neurofibromatosis 2.
Selvanathan SK; Shenton A; Ferner R; Wallace AJ; Huson SM; Ramsden RT; Evans DG
Clin Genet; 2010 Feb; 77(2):163-70. PubMed ID: 19968670
[TBL] [Abstract][Full Text] [Related]
14. Molecular characterization of novel germline deletions affecting SDHD and SDHC in pheochromocytoma and paraganglioma patients.
Bayley JP; Weiss MM; Grimbergen A; van Brussel BT; Hes FJ; Jansen JC; Verhoef S; Devilee P; Corssmit EP; Vriends AH
Endocr Relat Cancer; 2009 Sep; 16(3):929-37. PubMed ID: 19546167
[TBL] [Abstract][Full Text] [Related]
15. [Combining approach with multiplex PCR and MLPA to detect deletion and duplication in DMD patients, carriers, and prenatal diagnosis].
Li H; Ding J; Wang W; Chen Y; Lu W; Shao H; Wu BL
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2009 Jun; 26(3):318-22. PubMed ID: 19504448
[TBL] [Abstract][Full Text] [Related]
16. Molecular characterization of three novel Fanconi anemia mutations in Israeli Arabs.
Tamary H; Dgany O; Toledano H; Shalev Z; Krasnov T; Shalmon L; Schechter T; Bercovich D; Attias D; Laor R; Koren A; Yaniv I
Eur J Haematol; 2004 May; 72(5):330-5. PubMed ID: 15059067
[TBL] [Abstract][Full Text] [Related]
17. The neurofibromatosis 2 (NF2) tumour suppressor gene: implications beyond the hereditary tumour syndrome?
Kley N; Seizinger BR
Cancer Surv; 1995; 25():207-18. PubMed ID: 8718520
[TBL] [Abstract][Full Text] [Related]
18. Mutational analysis of the NF2 gene in sporadic meningiomas by denaturing high-performance liquid chromatography.
Kim JH; Kim IS; Kwon SY; Jang BC; Suh SI; Shin DH; Jeon CH; Son EI; Kim SP
Int J Mol Med; 2006 Jul; 18(1):27-32. PubMed ID: 16786152
[TBL] [Abstract][Full Text] [Related]
19. Characterization of deletion breakpoints in patients with dystrophinopathy carrying a deletion of exons 45-55 of the Duchenne muscular dystrophy (DMD) gene.
Miyazaki D; Yoshida K; Fukushima K; Nakamura A; Suzuki K; Sato T; Takeda S; Ikeda S
J Hum Genet; 2009 Feb; 54(2):127-30. PubMed ID: 19158820
[TBL] [Abstract][Full Text] [Related]
20. Intrafamilial correlation of clinical manifestations in neurofibromatosis 2 (NF2).
Zhao Y; Kumar RA; Baser ME; Evans DG; Wallace A; Kluwe L; Mautner VF; Parry DM; Rouleau GA; Joe H; Friedman JM
Genet Epidemiol; 2002 Oct; 23(3):245-59. PubMed ID: 12384977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
